NASDAQ:TEMP 7 January 2026 - 8 May 2026

Tempus AI locked in an upsized $400 million private sale of 0% convertible senior notes maturing in 2032, opting to swap out secured borrowings for debt with no periodic interest as it sharpens its focus on healthcare data and diagnostics. The deal, raised from the original $350 million, is slated for a May 12 close. Tempus plans to use the proceeds to pay off $307.7 million in loans, cover roughly $27.2 million for capped-call hedges, and for general corporate purposes.

Tempus AI Inc has set May 29 for its inaugural investor day, aiming to convince Wall Street it’s more than just a genetic testing company and can break into the broader healthcare data and AI market. That showcase follows its first-quarter earnings release, which lands on May 5—about three and a half weeks earlier.

Tempus AI, Inc. on Thursday announced it's teaming up with the Keck School of Medicine of USC and Keck Medicine of USC, setting the stage for its molecular testing, AI-powered care-gap analysis, and trial-matching tools to roll out across a major Southern California health system. The deal brings these technologies to USC Norris Comprehensive Cancer Center, Keck Hospital of USC, USC Verdugo Hills, plus other USC hospitals and clinics.